Patents by Inventor Carl R. Alving

Carl R. Alving has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5059591
    Abstract: Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.
    Type: Grant
    Filed: September 12, 1989
    Date of Patent: October 22, 1991
    Assignee: The Liposome Company, Inc.
    Inventors: Andrew S. Janoff, Mircea C. Popescu, Carl R. Alving, Michael W. Fountain, Robert P. Lenk, Marc J. Ostro, Paul A. Tremblay, Alan L. Weiner
  • Patent number: 4999344
    Abstract: Diacyl phosphatides having a polyunsaturated carboxylic acid at the 2 position are found to have cytotoxic effect against tumor cells. Subject compositions may be employed in vivo or in vitro for inhibiting tumor cell growth, either by themselves or in combination with other cytotoxic drugs. The compositions may be administered as liposomes.
    Type: Grant
    Filed: March 14, 1988
    Date of Patent: March 12, 1991
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Marti Jett-Tilton, Carl R. Alving
  • Patent number: 4897384
    Abstract: Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.
    Type: Grant
    Filed: March 24, 1986
    Date of Patent: January 30, 1990
    Assignee: The Liposome Company, Inc.
    Inventors: Andrew S. Janoff, Carl R. Alving, Michael W. Fountain, Robert P. Lenk, Marc J. Ostro, Mircea C. Popescu, Paul A. Tremblay, Alan L. Weiner
  • Patent number: 4885256
    Abstract: Monoclonal antibodies which demonstrate specific reactivity to cholesterol and methods for the detection of high levels of cholesterol by contacting biological specimens containing cholesterol with the monoclonal antibodies and measuring the formation of antigen-antibody complexes by immunosorbent assay.
    Type: Grant
    Filed: June 17, 1986
    Date of Patent: December 5, 1989
    Assignee: The United States of America as represented by the United States Army
    Inventors: Carl R. Alving, Glenn M. Swartz, Jr.
  • Patent number: 4863874
    Abstract: A method for the specific detection of inositol and phosphatidylinositol within a model membrane such as liposomes or within a cellular system such as T lymphocytes.
    Type: Grant
    Filed: July 11, 1986
    Date of Patent: September 5, 1989
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Nabila M. Wassef, Carl R. Alving
  • Patent number: 4416872
    Abstract: A novel treatment has been discovered for interrupting the life cycle of malaria parasite during its development in the liver of the vertebrate host. The subject invention involves a method of chemotherapy against sporozoite-induced malaria by administering an 8-aminoquinoline drug, such as primaquine, encapsulated within liposomes containing glycoconjugates, to a vertebrate host which has been infected with sporozoites of the parasites. Preferred species of glycoconjugates have a terminal glucose or galactose moiety, such as present in glycosyl ceramide, galactosyl ceramide, lactosyl ceramide, or in glycoproteins.
    Type: Grant
    Filed: March 17, 1982
    Date of Patent: November 22, 1983
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Carl R. Alving, Edgar A. Steck
  • Patent number: 4302459
    Abstract: An improved method is provided for the chemotherapy of leishmanial infects. An 8-aminoquinoline anti-leishmanial agent is encapsulated within liposomes and the liposome-encapsulated drug is injected into the body. Subject use of a liposome carrier has produced marked enhancement of the effectiveness of the drug against leishmanial parasites in the liver (such as characteristic of infections which are difficult to treat).
    Type: Grant
    Filed: March 19, 1980
    Date of Patent: November 24, 1981
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Edgar A. Steck, Carl R. Alving
  • Patent number: 4186183
    Abstract: An improved method is provided for the chemotherapy of leishmanial infections. The anti-leishmanial agent is encapsulated within liposomes and the liposome-encapsulated drug is injected into the body. Subject use of a liposome carrier has produced marked enhancement of the effectiveness and duration of anti-leishmanial action of meglumine antimoniate, and of sodium stibogluconate, drugs which are recommended widely for therapy of leishmaniasis.
    Type: Grant
    Filed: March 29, 1978
    Date of Patent: January 29, 1980
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Edgar A. Steck, Carl R. Alving